Agios Pharmaceuticals, developer of AG-348, or mitapivat, reported that preliminary phase I trial data showed the drug safely boosted hemoglobin amounts and altered biomarker levels of red blood damage in adult patients with sickle cell disease. The NIH-backed trial is already underway and aims to enroll 25 participants, with patient recruitment currently ongoing.
Agios: Mitapivat shows positive effect on hemoglobin of SCD patients
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.